TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15194366
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg/dose every 14 days for five doses (group I, n = 107)
Study: 15194366
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg/dose every 14 days for two doses (group II, n = 112)
Study: 15194366
Drug: No-antibody induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-antibody induction (group III, n = 78)
Study: 11212085
Drug: Spiroflor SRL
Normalized name: ExoSCRT Derma Signal Kit SRLV KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiroflor SRL gel (SRL)
Study: 8280513
Drug: General practitioners'
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioners' clinical decision to give thrombolytic therapy
Study: 2943192
Drug: Midazolam, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, 0.2 mg/kg
Study: 2943192
Drug: Thiopental, 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental, 3.5 mg/kg
Study: 27267228
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (1 g)
Study: 27267228
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1 g)
Study: 24820653
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN)
Study: 9004094
Drug: ACE-inhibitor benazepril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor benazepril
Study: 1804654
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg sodium benzoate
Study: 1804654
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg sodium benzoate
Study: 1804654
Drug: 160 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/kg sodium benzoate
Study: 1804654
Drug: 80 to
Normalized name: ALCOHOL 354.4 mL in 80 TOPICAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 to 160 mg/kg sodium benzoate
Study: 6383991
Drug: Neostigmin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmin (3 x 0.5 mg/die)
Study: 30832624
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm with quarterly booster visits for 6 months
Study: 26702455
Drug: Intranasal atomised
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal atomised dexmedetomidine (DEX) 2 μg/kg
Study: 24581948
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (14 patients)
Study: 22138037
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (6 cycles of paclitaxel 70 mg/m(2)/wk [3 weeks on/1 week off])
Study: 25790233
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rectal indomethacin
Study: 1858625
Drug: Heparin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin pretreatment with treadmill exercise (5000 IU intravenously)
Study: 1858625
Drug: Heparin calcium
Normalized name: HEPARIN CALCIUM
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin calcium injections (10,000 IU subcutaneously)
Study: 31295547
Drug: Stannum metallicum
Normalized name: Stannum Metallicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stannum metallicum 30x preparation
Study: 28276743
Drug: Social modelling
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social modelling (observing positive treatment effects)
Study: 25621236
Drug: Miconazole cream
Normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole cream
Study: 18761755
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) training for nurses
Study: 15369420
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trandolapril (ACE inhibitor) and losartan (ARB)
Study: 12904684
Drug: Captopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (ACE inhibitor)
Study: 30442080
Drug: Trandolapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (ACE inhibitor)
Study: 8518380
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dobutamine and nitroprusside
Study: 3088751
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (group 2)
Study: 3088751
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluids (group 1)
Study: 30400222
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of agraz nectar
Study: 24971661
Drug: AMG 745
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 745 (3 mg/kg)
Study: 20171425
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) formulation of simvastatin 40 mg
Study: 20171425
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation of simvastatin 40 mg
Study: 20171425
Drug: Both CR
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CR and IR formulations
Study: 14572817
Drug: Intravenous purified,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous purified, pasteurized C1 esterase inhibitor concentrate (Berinert® P) at doses of 500‐1000 IU
Study: 8753712
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 gram intravenously administered preoperatively and again 15 minutes before skin incision.
Study: 25764097
Drug: Ototopical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ototopical and systemic antibiotics
Study: 15712767
Drug: Poi consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poi consumption (130 g/meal, three times a day for 4 weeks)
Study: 12908031
Drug: Brazilian DTPw/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian DTPw/Hib combination
Study: 12908031
Drug: European DTPw/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: European DTPw/Hib combination
Study: 6645208
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate therapy (60 mEq/day)
Study: 6645208
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate therapy
Study: 27132200
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mifepristone (200mg oral, 36h before surgery) and misoprostol (400μg oral, 3h before surgery)
Study: 27132200
Drug: Misoprostol (400μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400μg oral, 3h before surgery)
Study: 27132200
Drug: Mifepristone (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200mg oral, 36h before surgery)
Study: 27132200
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mifepristone and misoprostol
Study: 25168098
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients with previous CABG
Study: 10732318
Drug: Metoclopramide 5
Normalized name: metoclopramide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 5 mg
Study: 15535488
Drug: Metoclopramide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 2.5 mg
Study: 11832254
Drug: Individualised educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised educational behavioural treatment delivered by cardiac nurses in hospital
Study: 8293756
Drug: Sotalol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol therapy
Study: 8293756
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of prior antiarrhythmic therapy
Study: 8293756
Drug: Long-term follow-up
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term follow-up of patients discharged on a drug predicted to be effective
Study: 3720045
Drug: Nifedipine, Metoprolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, Metoprolol, or Isosorbide Dinitrate (therapy period)
Study: 3720045
Drug: Placebo (absence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (absence of therapy)
Study: 16274414
Drug: CRT-D (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D (Cardiac Resynchronization Therapy with Defibrillator)
Study: 19827465
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg/kg body mass
Study: 10486670
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10-40 mg/day) possibly associated with enalapril (5-20 mg/day) and/or hydrochlorothiazide (12.5-25 mg/day)
Study: 8961036
Drug: Moclobemide (300-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300-450 mg daily)
Study: 7593728
Drug: Fluoxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-40 mg daily)
Study: 25670364
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 injections (subcutaneous)
Study: 24313693
Drug: Web‐based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web‐based acceptance and commitment therapy (ACT)
Study: 11679600
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (10 mL sprayed onto the wound before tourniquet deflation and wound closure)
Study: 8083097
Drug: Accelerated multiple
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated multiple daily fraction radiation (44.40 Gy in 12 fractions, 3.7 Gy BID)
Study: 2577482
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg nocte for 4 weeks
Study: 2577482
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg nocte for 4 weeks
Study: 2577482
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg nocte for 4 weeks
Study: 334210
Drug: Pentazocine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.6 mg/kg
Study: 22630616
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg for the first 5 days and 100 mg on days 6 and 7)
Study: 22093474
Drug: DTaP-IPV//PRP-T combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP-T combined vaccine (PENTAXIM(TM)) vaccinated at 2, 3, 4 months of age
Study: 22093474
Drug: DTaP-IPV//PRP-T combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP-T combined vaccine (PENTAXIM(TM)) vaccinated at 3, 4, 5 months of age
Study: 22093474
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: DTaP, Hib tetanus conjugate (Act-HIB(TM)), and IPV (IMOVAX PolioTM(TM)) vaccines vaccinated at 3, 4, 5 months of age
Study: 22093474
Drug: DTaP-IPV//PRP-T combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP-T combined vaccine
Study: 15209605
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg twice daily for 6 months
Study: 15209605
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg twice daily for 12 months
Study: 11270027
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL 0.9% saline (Group A)
Study: 11270027
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL 1% lidocaine (Group B)
Study: 11270027
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL dexamethasone (4 mg) (Group C)
Study: 9266515
Drug: pravastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin (10-40 mg/day)
Study: 9266515
Drug: lovastatin (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (20-80 mg/day)
Study: 3334238
Drug: Carbon fibre
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon fibre augmentation
Study: 3334238
Drug: Primary suture
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary suture vs Carbon fibre augmentation
Study: 22402617
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + DL (scaling, root planing, and diode laser treatment)
Study: 2566251
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg kg‐1
Study: 3351267
Drug: povidone‐iodine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: povidone‐iodine solution
Study: 27716209
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (10-weekly intramuscular injections for 56 weeks)
Study: 21353106
Drug: Pregabalin (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150-600 mg/d)
Study: 16680957
Drug: Combined FE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined FE enzymes (50 ml dissolved in 0‐150 ml normal saline to reach the final concentration of 1‐3 U/ml)
Study: 9504644
Drug: Oestrogen monotherapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen monotherapy
Study: 21828339
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and C-peptide response
Study: 19126625
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HPLC‐purified DHEA/d orally for 12 months
Study: 17124720
Drug: DiaPep277 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DiaPep277 (1 mg)
Study: 9357387
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg
Study: 7811056
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg with 30 ml high potency antacid
Study: 2809052
Drug: Prompted voiding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompted voiding treatment (hourly checks, asking for toileting assistance, social reinforcement)
Study: 2809052
Drug: Prompted voiding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompted voiding treatment
Study: 31971279
Drug: Physiotherapy modalities
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy modalities (superficial heating and transcutaneous electrical nerve stimulation) and exercise therapy
Study: 30585257
Drug: HD-FOLFIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-FOLFIRI (irinotecan dose 300 mg/m2 for UGT1A1*1/*1 and 260 mg/m2 for *1/*28)
Study: 30585257
Drug: FOLFIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (irinotecan dose 180 mg/m2)
Study: 28243021
Drug: modified L‐haptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified L‐haptic IOL
Study: 24804018
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Wellmune WGP(R) beta‐1,3/1,6‐Glucan daily for 4 weeks
Study: 24804018
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg placebo (rice flour) daily for 4 weeks
Study: 22068444
Drug: Daily sport
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sport activity during the school day (1 hour of regulated sport exercise, including 15 min of endurance training, five days a week)
Study: 22068444
Drug: Daily sport
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sport activity during the school day
Study: 19935991
Drug: Percutaneous adhesiolysis
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous adhesiolysis with targeted delivery and injection of lidocaine, 10% hypertonic sodium chloride solution, and non‐particulate Betamethasone.
Study: 19935991
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with catheterization up to S3 with local anesthetic, 0.9% sodium chloride solution, non‐particulate betamethasone.
Study: 15936866
Drug: Naltrexone (opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (opiate antagonist)
Study: 10636456
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin (40 mg once daily)
Study: 2131899
Drug: Nicardipine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine administered at doses of 10 mg/h, 12.5 mg/h, and 15.0 mg/h for 5 minutes, 5 minutes, and 15 minutes, respectively.
Study: 2131899
Drug: Nicardipine during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine during maintenance period at an infusion rate reduced to 3.0 mg/h, adjusted by 1.0 to 2.5 mg/h every 15 minutes as needed.
Study: 2131899
Drug: Baseline measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline measurement of plasma norepinephrine (NE) concentrations prior to nicardipine infusion.
Study: 2131899
Drug: Nicardipine treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine treatment.
Study: 355601
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 1200 mg daily
Study: 30878623
Drug: mHealth augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth augmented social support training (daily text-messages that synchronize with the patient messages)
Study: 24273967
Drug: Chinese medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medical treatment (Shen invigorating and blood activating, Shen invigorating and Pi supplementing, Shen‐qi benefiting)
Study: 24273967
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical treatment (Clomifene, 25 mg per day)
Study: 21574782
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU cholecalciferol by dropper (1 mL syrup)
Study: 16723246
Drug: Intermittent antegrade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antegrade cold crystalloid (CC)
Study: 11216500
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran biscuit (7.5 g/day) for 12 weeks
Study: 11216500
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran biscuit (15 g/day) for 12 weeks
Study: 4038159
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15 g daily for 4 weeks)
Study: 4038159
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil supplement (15 g daily for 4 weeks)
Study: 28729021
Drug: Ceritinib 600
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 600 mg with food
Study: 24301237
Drug: Full-face injections
Normalized name: bald-faced hornet venom protein Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-face injections of abobotulinum toxin A (ABO) at doses of 120-165 U
Study: 24301237
Drug: Full-face injections
Normalized name: bald-faced hornet venom protein Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-face injections of abobotulinum toxin A (ABO) at doses of 166-205 U
Study: 24301237
Drug: Full-face injections
Normalized name: bald-faced hornet venom protein Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-face injections of abobotulinum toxin A (ABO) at doses of 206-250 U
Study: 22080324
Drug: Betaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (2.5 g mixed in 500 ml of Gatorade®)
Study: 22080324
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 ml of Gatorade®)
Study: 14691990
Drug: 18-g needle
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18-g needle
Study: 14691990
Drug: 20-mL syringe
Normalized name: thiopental
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-mL syringe
Study: 14691990
Drug: 20-g needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-g needle
Study: 30580488
Drug: 5-mL syringe
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mL syringe
Study: 11425979
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PPP and PVP imaging
Study: 30358109
Drug: Golimumab (anti-TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (anti-TNF antibody)
Study: 30358109
Drug: Mavrilimumab (GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (GM-CSF receptor antibody)
Study: 28546090
Drug: Cabotegravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir (800 mg intramuscular injections every 12 weeks)
Study: 28546090
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline injections every 12 weeks)
Study: 28546090
Drug: Cabotegravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir (800 mg intramuscular injections)